Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan + anlotinib for second-line advanced gastric cancer (single-arm phase II)
ChiCTR2500112073Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Nov 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sacituzumab tirumotecan and anlotinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-free survival (PFS). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecananlotinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500112073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112073.